{"generic":"Erlotinib Hydrochloride","drugs":["Erlotinib Hydrochloride","Tarceva"],"mono":{"0":{"id":"930518-s-0","title":"Generic Names","mono":"Erlotinib Hydrochloride"},"1":{"id":"930518-s-1","title":"Dosing and Indications","sub":[{"id":"930518-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Carcinoma of pancreas, Locally advanced, unresectable, or metastatic, first line treatment in combination with gemcitabine:<\/b> 100 mg ORALLY 1 hour before or 2 hours after ingestion of food once daily, in combination with gemcitabine 1000 mg\/m(2) IV weekly for 7 weeks followed by 1-week rest (cycle 1), then 1000 mg\/m(2) IV weekly for 3 weeks followed by 1-week rest (subsequent cycles); treat until disease progression or unacceptable toxicity<\/li><li><b>Non-small cell lung cancer, Locally advanced or metastatic, as monotherapy:<\/b> 150 mg ORALLY 1 hour before or 2 hours after ingestion of food once daily until disease progression or unacceptable toxicity<\/li><li><b>Non-small cell lung cancer, Metastatic, first-line therapy, EGFR exon 19 deletions or exon 21 substitution mutations:<\/b> 150 mg ORALLY 1 hour before or 2 hours after ingestion of food once daily until disease progression or unacceptable toxicity<\/li><\/ul>"},{"id":"930518-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness have not been established in pediatric patients "},{"id":"930518-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal toxicity, grade 3 or 4:<\/b> interrupt erlotinib until condition is resolved and consider discontinuation of use<\/li><li><b>hepatic impairment or biliary obstruction (preexisting):<\/b> for a 2-fold increase of total bilirubin or a 3-fold increase of transaminases above baseline impairment, interrupt erlotinib and discontinue use if significant improvement or resolution does not occur within 3 weeks<\/li><li><b>hepatotoxicity (normal baseline values):<\/b> for a total bilirubin greater than 3 x ULN or transaminases greater than 5 x ULN, interrupt erlotinib and discontinue use if significant improvement or resolution does not occur within 3 weeks<\/li><li><b>cigarette smoking:<\/b> increase the dose by 50-mg increments at 2-week intervals, to a maximum of 300 mg\/day; immediately reduce the dose if smoking cessation occurs<\/li><li><b>concomitant CYP3A4 inducers (eg, rifampin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, or St John's wort):<\/b> avoid concurrent use if possible; increase the dose by 50-mg increments at 2-week intervals, to a maximum of 450 mg\/day<\/li><li><b>concomitant strong CYP3A4 inhibitors (eg, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, grapefruit, or grapefruit juice):<\/b> avoid concurrent use if possible; may require dose reduction in 50-mg decrements if severe reactions occur<\/li><li><b>concomitant inhibitor of both CYP3A4 and CYP1A2 (eg, ciprofloxacin):<\/b> avoid concurrent use if possible; may require dose reduction in 50-mg decrements if severe reactions occur<\/li><li><b>diarrhea, severe and persistent (unresponsive to loperamide):<\/b> interrupt erlotinib until condition is resolved to baseline or grade 1 or less; restart erlotinib with a daily dose reduction by 50 mg<\/li><li><b>keratitis (grade 3 or 4 or for grade 2 lasing more than 2 weeks):<\/b> interrupt erlotinib until condition is resolved to baseline or grade 1 or less in severity; restart erlotinib with a daily dose reduction by 50 mg; permanently discontinue use if corneal perforation or severe ulceration occur<\/li><li><b>interstitial lung disease:<\/b> interrupt erlotinib during diagnostic evaluation; permanently discontinue if confirmed<\/li><li><b>ocular disorders (acute worsening):<\/b> interrupt erlotinib until condition is resolved and consider discontinuation of use<\/li><li><b>rash, severe (unresponsive to medical treatment):<\/b> interrupt erlotinib until condition is resolved to baseline or grade 1 or less; restart erlotinib with a daily dose reduction by 50 mg; discontinue for severe bullous or exfoliating skin conditions<\/li><\/ul>"},{"id":"930518-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Carcinoma of pancreas, Locally advanced, unresectable, or metastatic, first line treatment in combination with gemcitabine<\/li><li>Non-small cell lung cancer, Locally advanced or metastatic, as monotherapy<\/li><li>Non-small cell lung cancer, Metastatic, first-line therapy, EGFR exon 19 deletions or exon 21 substitution mutations<\/li><\/ul>"}]},"3":{"id":"930518-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930518-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930518-s-3-10","title":"Precautions","mono":"<ul><li>cerebrovascular accidents, including a fatality, have been reported<\/li><li>cigarette smoking; dose adjustment recommended<\/li><li>concomitant use with CYP3A4 inducers (eg, St John's wort, phenobarbital, carbamazepine, phenytoin, rifapentine, rifabutin, rifampin); avoid if possible; dose adjustment recommended<\/li><li>concomitant use with dual CYP3A4 and CYP1A2 inhibitors (eg, ciprofloxacin); avoid concurrent use if possible; dose reduction may be required<\/li><li>concomitant use with proton pump inhibitors; avoid concomitant use if possible<\/li><li>concomitant use with strong CYP3A4 inhibitors (eg, grapefruit or grapefruit juice, voriconazole, troleandomycin, telithromycin, saquinavir, ritonavir, nelfinavir, nefazodone, ketoconazole, itraconazole, indinavir, clarithromycin, atazanavir); avoid concurrent use if possible; dose reduction may be required<\/li><li>concomitant use with warfarin or other coumarin-derivative anticoagulants; bleeding events, including fatalities, have been reported; monitoring recommended<\/li><li>corneal perforation and severe ulceration may occur; decreased tear production, abnormal eyelash growth, keratoconjunctivitis sicca, and keratitis have occurred and may increase risk; interrupt or discontinue use<\/li><li>diarrhea, severe and not responsive to loperamide; interruption of therapy and dose adjustment recommended<\/li><li>gastrointestinal (GI) perforation, life-threatening, may occur; increased risk with peptic ulceration or diverticular disease and with concomitant anti-angiogenic agents, corticosteroids, NSAIDs, and\/or taxane-based chemotherapy; permanently discontinue therapy if a GI perforation occurs<\/li><li>hepatotoxicity, including hepatic failure and hepatorenal syndrome, with fatalities, has been reported, particularly among patients with baseline hepatic impairment; monitoring recommended; therapy interruption and discontinuation may be required<\/li><li>hepatic impairment or biliary obstruction; increased risk for hepatotoxicity, especially in patients with total bilirubin more than 3 times ULN; monitoring recommended; therapy interruption and discontinuation may be required<\/li><li>interstitial lung disease (ILD), including fatal cases, has occurred; in the event of acute onset of new or progressive, unexplained pulmonary symptoms (eg, dyspnea, cough, fever), withhold erlotinib during diagnostic evaluation; discontinue therapy if ILD confirmed<\/li><li>keratitis, grade 3 to 4 or grade 2 for more than 2 weeks; interruption of therapy and dose adjustment recommended<\/li><li>microangiopathic hemolytic anemia with thrombocytopenia has been reported<\/li><li>myocardial infarction\/ischemia (including fatality) has been reported<\/li><li>ocular disorders (eg, eye pain), acute or worsening; therapy interruption and discontinuation may be required<\/li><li>rash, severe and not responsive to medical therapy; interruption of therapy and dose adjustment recommended<\/li><li>renal insufficiency, hepatorenal syndrome, and acute renal failure (including fatalities) have been reported; hepatic impairment and severe dehydration may increase risk; monitoring recommended; therapy interruption and discontinuation may be required<\/li><li>skin disorders, severe (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis), with fatalities, have been reported; discontinue therapy with severe bullous, blistering, or exfoliative skin conditions<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930518-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Erlotinib: D (FDA)<\/li><li>Erlotinib: C (AUS)<\/li><\/ul>"},{"id":"930518-s-3-12","title":"Breast Feeding","mono":"Erlotinib: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930518-s-4","title":"Drug Interactions","sub":{"1":{"id":"930518-s-4-14","title":"Major","mono":"<ul><li>Acenocoumarol (theoretical)<\/li><li>Apazone (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Aspirin (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Atorvastatin (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Bromfenac (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Celecoxib (theoretical)<\/li><li>Ciprofloxacin (probable)<\/li><li>Clarithromycin (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Dexlansoprazole (theoretical)<\/li><li>Diclofenac (theoretical)<\/li><li>Dicumarol (theoretical)<\/li><li>Diflunisal (theoretical)<\/li><li>Efavirenz (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Esomeprazole (theoretical)<\/li><li>Etodolac (theoretical)<\/li><li>Fenoprofen (theoretical)<\/li><li>Flurbiprofen (theoretical)<\/li><li>Fluvastatin (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Ibuprofen (theoretical)<\/li><li>Ibuprofen Lysine (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Indomethacin (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (probable)<\/li><li>Ketoprofen (theoretical)<\/li><li>Ketorolac (theoretical)<\/li><li>Lansoprazole (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lovastatin (theoretical)<\/li><li>Magnesium Salicylate (theoretical)<\/li><li>Meclofenamate (theoretical)<\/li><li>Mefenamic Acid (theoretical)<\/li><li>Meloxicam (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nabumetone (theoretical)<\/li><li>Naproxen (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nepafenac (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Omeprazole (probable)<\/li><li>Oxaprozin (theoretical)<\/li><li>Pantoprazole (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenprocoumon (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Piroxicam (theoretical)<\/li><li>Pitavastatin (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Pravastatin (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Rabeprazole (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Rosuvastatin (theoretical)<\/li><li>Salicylic Acid (theoretical)<\/li><li>Salsalate (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Simvastatin (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Sulindac (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Tolmetin (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Verapamil (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Warfarin (probable)<\/li><\/ul>"},"2":{"id":"930518-s-4-15","title":"Moderate","mono":"<ul><li>Aluminum Carbonate, Basic (probable)<\/li><li>Aluminum Hydroxide (probable)<\/li><li>Aluminum Phosphate (probable)<\/li><li>Calcium Carbonate (probable)<\/li><li>Dihydroxyaluminum Aminoacetate (probable)<\/li><li>Dihydroxyaluminum Sodium Carbonate (probable)<\/li><li>Magaldrate (probable)<\/li><li>Magnesium Carbonate (probable)<\/li><li>Magnesium Hydroxide (probable)<\/li><li>Magnesium Oxide (probable)<\/li><li>Magnesium Trisilicate (probable)<\/li><li>Ranitidine (probable)<\/li><\/ul>"}}},"5":{"id":"930518-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Edema (37%)<\/li><li><b>Dermatologic:<\/b>Alopecia (14%), Pruritus (13% to 16%), Rash, Any grade (60% to 85%)<\/li><li><b>Endocrine metabolic:<\/b>Weight decreased (39%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (11% to 46%), Diarrhea, Any grade (20% to 62%), Flatulence (13%), Indigestion (17%), Inflammatory disease of mucous membrane (17% to 22%), Loss of appetite (52%), Nausea (33% to 60%), Vomiting (23% to 42%)<\/li><li><b>Hepatic:<\/b>Hyperbilirubinemia, Increased liver enzymes<\/li><li><b>Immunologic:<\/b>Infectious disease (24% to 39%)<\/li><li><b>Musculoskeletal:<\/b>Bone pain (25%), Myalgia (21%)<\/li><li><b>Neurologic:<\/b>Headache (15%)<\/li><li><b>Ophthalmic:<\/b>Conjunctivitis (12% to 18%), Keratoconjunctivitis sicca (12%)<\/li><li><b>Psychiatric:<\/b>Anxiety (13%), Depression (19%)<\/li><li><b>Respiratory:<\/b>Cough (16% to 48%), Dyspnea, Any grade (41% to 45%)<\/li><li><b>Other:<\/b>Fatigue (52%), Fever (36%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac dysrhythmia, Grade 3 or higher, Myocardial infarction, Syncope, Grade 3 or higher<\/li><li><b>Dermatologic:<\/b>Rash, Grade 3 or 4 (5% to 14%), Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Gastrointestinal:<\/b>Bowel obstruction, Grade 3 or higher, Diarrhea, Grade 3 or 4 (2% to 5%), Gastrointestinal hemorrhage, Gastrointestinal perforation, Pancreatitis, Grade 3 or higher<\/li><li><b>Hematologic:<\/b>Deep venous thrombosis (3.9%), Microangiopathic hemolytic anemia, With thrombocytopenia (up to 1.4%)<\/li><li><b>Hepatic:<\/b>Hepatorenal syndrome, Liver failure<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident (2.5%)<\/li><li><b>Ophthalmic:<\/b>Corneal ulcer, Perforation of cornea<\/li><li><b>Renal:<\/b>Acute renal failure<\/li><li><b>Respiratory:<\/b>Dyspnea, Grade 3 or 4 (8% to 17%), Interstitial lung disease<\/li><\/ul>"},"6":{"id":"930518-s-6","title":"Drug Name Info","sub":{"0":{"id":"930518-s-6-17","title":"US Trade Names","mono":"Tarceva<br\/>"},"2":{"id":"930518-s-6-19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>Tyrosine Kinase Inhibitor<\/li><\/ul>"},"3":{"id":"930518-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930518-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930518-s-7","title":"Mechanism Of Action","mono":"Erlotinib hydrochloride reversibly inhibits tyrosine kinase activity of the epidermal growth factor receptor (EGFR), which results in the inhibition of autophosphorylation of tyrosine residues associated with EGFR and dampened tumor cell signalling, survival, and proliferation.<br\/>"},"8":{"id":"930518-s-8","title":"Pharmacokinetics","sub":[{"id":"930518-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 4 hours<\/li><li>Bioavailability, Oral: about 60%<\/li><li>Effect of food: increases bioavailability to almost 100%;  administer on an empty stomach<\/li><\/ul>"},{"id":"930518-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 232 L<\/li><li>Protein binding: approximately 93%<\/li><\/ul>"},{"id":"930518-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic: primary site via CYP3A4 and CYP1A2<\/li><li>O-demethylated derivative (OSI-420): unknown<\/li><li>substrate of CYP3A4, CYP1A2, and CYP1A1<\/li><\/ul>"},{"id":"930518-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 83%, 1% unchanged<\/li><li>Renal: 8%, 0.3% unchanged<\/li><li>Total body clearance: cancer patients, 5.3 L\/hr; cigarette smokers, 24% higher rate of clearance<\/li><\/ul>"},{"id":"930518-s-8-27","title":"Elimination Half Life","mono":"36.2 hours <br\/>"}]},"9":{"id":"930518-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>administer on an empty stomach 1 hour before or 2 hours after food<\/li><li>separate erlotinib administration time from concurrent antacid by several hours<\/li><li>administer erlotinib 10 hours after a dose of an H2 blocker (eg, ranitidine) and at least 2 hours before next dose of H2 blocker<\/li><\/ul>"},"10":{"id":"930518-s-10","title":"Monitoring","mono":"<ul><li>evidence of tumor response may be indicative of efficacy<\/li><li>liver function tests; periodically in all patients, and more frequently in patients with biliary obstruction or hepatic impairment (total bilirubin greater than the ULN or Child-Pugh A, B, C)<\/li><li>renal function; periodically especially in patients at risk of dehydration<\/li><li>serum electrolytes; periodically especially in patients at risk of dehydration<\/li><\/ul>"},"11":{"id":"930518-s-11","title":"How Supplied","mono":"<b>Tarceva<\/b><br\/>Oral Tablet: 25 MG, 100 MG, 150 MG<br\/>"},"12":{"id":"930518-s-12","title":"Toxicology","sub":[{"id":"930518-s-12-31","title":"Clinical Effects","mono":"<b> ERLOTINIB <\/b><br\/>OVERDOSE: Data are limited. The signs and symptoms of an acute overdose are expected to be comparable to those side effects seen with high dose therapy (eg, diarrhea, abdominal pain, rash, and liver transaminase elevation). ADVERSE EFFECTS: The most frequently reported adverse effects are rash and diarrhea. Patients may also commonly report nausea, vomiting, abdominal pain, anorexia, and fatigue. Dyspnea and cough are less commonly reported. Signs attributed to adverse drug reaction include mucositis, conjunctivitis, keratitis, and trichomegaly. Common abnormal lab values include elevated liver enzymes, neutropenia, and anemia. The development of interstitial lung disease has also been associated with erlotinib therapy, and may be severe. Rare cases of hepatic failure and hepatorenal syndrome have been reported, some resulting in fatalities.<br\/>"},{"id":"930518-s-12-32","title":"Treatment","mono":"<b> ERLOTINIB <\/b><br\/><ul><li>Decontamination: Activated charcoal.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Myelosuppression: There is little data on the use of hematopoietic colony stimulating factors to treat neutropenia. It may be considered in patients with neutropenia at significant risk for developing febrile neutropenia. Filgrastim (Adult) - starting dose is 5 mcg\/kg\/day by IV infusion or subQ injection. Sargramostim: Usual dose 250 mcg\/square meter\/day infused IV over 4 hrs. Recombinant human erythropoietin may be used to prevent or correct antineoplastic-induced anemia.<\/li><li>Monitoring of patient: Monitor the following laboratory studies in symptomatic or overdose patients: CBC with differential, liver function, fluid and electrolyte status in patients with significant vomiting and\/or diarrhea. Obtain chest x-ray, ABGs in patients with acute respiratory signs\/symptoms.<\/li><\/ul>"},{"id":"930518-s-12-33","title":"Range of Toxicity","mono":"<b> ERLOTINIB <\/b><br\/>TOXICITY: A minimum toxic dose has not been established. Single oral doses of 1,000 mg to 1,600 mg have been tolerated by healthy adults. Repeat twice-daily doses of erlotinib 200 mg for only a few days; however, was not tolerated due to severe diarrhea, rash and liver transaminase elevation. THERAPEUTIC DOSE: Adult: 150 milligrams once daily for non-small cell lung cancer; 100 milligrams once daily in combination with gemcitabine for pancreatic cancer. Pediatric: Safety and efficacy not established. <br\/>"}]},"13":{"id":"930518-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to immediately report symptoms of a myocardial infarction or cerebrovascular accident.<\/li><li>Instruct patient to report symptoms of serious gastrointestinal events (eg, bleeding, ulceration, perforation) or hepatotoxicity.<\/li><li>Recommend female patient use reliable contraception to avoid pregnancy during therapy and for at least 14 days after the last dose.<\/li><li>Drug may cause rash, diarrhea, anorexia, nausea, vomiting, conjunctivitis, or fatigue.<\/li><li>Instruct patient to immediately report symptoms of a bullous, blistering, or exfoliative skin condition (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis).<\/li><li>Advise patient to report new onset or worsening of unexplained pulmonary symptoms (eg, dyspnea, cough).<\/li><li>Counsel patient to report abnormal eyelash growth or symptoms of keratoconjunctivitis sicca, keratitis, or corneal perforation\/ulceration.<\/li><li>Instruct patient to take drug 1 hour before or 2 hours after food.<\/li><li>Advise patient to avoid grapefruit or grapefruit juice with drug.<\/li><li>Warn patient to report change in status of cigarette smoking, as dose modification is necessary.<\/li><\/ul>"}}}